Soligenix, Inc., a late-stage biopharmaceutical company, today announced that it has entered into a definitive license agreement with the University of Colorado (CU) for novel technology for use in the development of subunit vaccines with long-term stability, including stability at elevated temperatures. Soligenix has been developing this stabilization technology under an option-to-license agreement from CU that was initiated to support the technology development efforts funded by a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID). The underlying technology has been developed by Drs. Amber Clausi, John Carpenter and Theodore Randolph at CU.
Read the full release from Soligenix.
7 hours ago